198 related articles for article (PubMed ID: 30789768)
1. Pharmaceutical Industry Support of US Patient Advocacy Organizations: An International Context.
Kang SY; Bai G; Karas L; Anderson GF
Am J Public Health; 2019 Apr; 109(4):559-561. PubMed ID: 30789768
[TBL] [Abstract][Full Text] [Related]
2. Patient Advocacy Organizations, Industry Funding, and Conflicts of Interest.
Rose SL; Highland J; Karafa MT; Joffe S
JAMA Intern Med; 2017 Mar; 177(3):344-350. PubMed ID: 28114624
[TBL] [Abstract][Full Text] [Related]
3. [Transparency in relations between multinational R&D pharmaceutical companies' corporate social responsibility activities and patient organizations in the Europe, Japan, and the United States].
Kato M; Ishikawa H; Okuhara T; Kiuchi T
Nihon Koshu Eisei Zasshi; 2019; 66(12):746-755. PubMed ID: 31875625
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and Disclosure of Potential Conflicts of Interest in Dermatology Patient Advocacy Organizations.
Li DG; Singer S; Mostaghimi A
JAMA Dermatol; 2019 Apr; 155(4):460-464. PubMed ID: 30698625
[TBL] [Abstract][Full Text] [Related]
5. Industry Support of Patient Advocacy Organizations: The Case for an Extension of the Sunshine Act Provisions of the Affordable Care Act.
McCoy MS
Am J Public Health; 2018 Aug; 108(8):1026-1030. PubMed ID: 29927655
[TBL] [Abstract][Full Text] [Related]
6. Health advocacy organizations and the pharmaceutical industry: an analysis of disclosure practices.
Rothman SM; Raveis VH; Friedman A; Rothman DJ
Am J Public Health; 2011 Apr; 101(4):602-9. PubMed ID: 21233424
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015.
Ozieranski P; Csanadi M; Rickard E; Tchilingirian J; Mulinari S
JAMA Netw Open; 2019 Jun; 2(6):e196253. PubMed ID: 31225896
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan.
Saito H; Ozaki A; Sawano T; Shimada Y; Tanimoto T
JAMA Netw Open; 2019 Apr; 2(4):e192834. PubMed ID: 31026027
[TBL] [Abstract][Full Text] [Related]
9. Assessing stakeholder opinion on relations between cancer patient groups and pharmaceutical companies in Europe.
Leto di Priolo S; Fehervary A; Riggins P; Redmond K
Patient; 2012; 5(2):127-39. PubMed ID: 22299759
[TBL] [Abstract][Full Text] [Related]
10. Patient advocacy organizations: institutional conflicts of interest, trust, and trustworthiness.
Rose SL
J Law Med Ethics; 2013; 41(3):680-7. PubMed ID: 24088159
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK.
Rickard E; Ozieranski P; Mulinari S
Health Policy; 2019 Dec; 123(12):1244-1250. PubMed ID: 31455562
[TBL] [Abstract][Full Text] [Related]
12. Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries.
Fabbri A; Santos A; Mezinska S; Mulinari S; Mintzes B
Int J Health Policy Manag; 2018 Jun; 7(6):504-509. PubMed ID: 29935127
[TBL] [Abstract][Full Text] [Related]
13. Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs.
Mulinari S; Vilhelmsson A; Rickard E; Ozieranski P
PLoS One; 2020; 15(6):e0235021. PubMed ID: 32579571
[TBL] [Abstract][Full Text] [Related]
14. A Content Analysis of Patient Advocacy Organization Policies Addressing Institutional Conflicts of Interest.
Brems JH; McCoy MS
AJOB Empir Bioeth; 2019; 10(4):215-221. PubMed ID: 31593523
[No Abstract] [Full Text] [Related]
15. Analysis of Potential Conflicts of Interest among Otolaryngologic Patient Advocacy Organizations in 2016.
Kondamuri NS; Rathi VK; Naunheim MR; Sethi RV; Miller AL; Varvares MA
Otolaryngol Head Neck Surg; 2019 Dec; 161(6):967-969. PubMed ID: 31479391
[TBL] [Abstract][Full Text] [Related]
16. Patient organizations' funding from pharmaceutical companies: is disclosure clear, complete and accessible to the public? An Italian survey.
Colombo C; Mosconi P; Villani W; Garattini S
PLoS One; 2012; 7(5):e34974. PubMed ID: 22590498
[TBL] [Abstract][Full Text] [Related]
17. Industry funding of patient organisations in the UK: a retrospective study of commercial determinants, funding concentration and disease prevalence.
Gentilini A; Parvanova I
BMJ Open; 2023 Jun; 13(6):e071138. PubMed ID: 37369404
[TBL] [Abstract][Full Text] [Related]
18. Coalition Priorité Cancer and the pharmaceutical industry in Quebec: conflicts of interest in the reimbursement of expensive cancer drugs?
Hughes D; Williams-Jones B
Healthc Policy; 2013 Aug; 9(1):52-64. PubMed ID: 23968674
[TBL] [Abstract][Full Text] [Related]
19. [Conflict of interest regarding clinical physicians' relationship with pharmaceutical industry and medical education].
Miyata Y
Seishin Shinkeigaku Zasshi; 2010; 112(11):1136-45. PubMed ID: 21226250
[TBL] [Abstract][Full Text] [Related]
20. Disclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise?
Pashley D; Ozieranski P; Mulinari S
Int J Health Serv; 2022 Jul; 52(3):347-362. PubMed ID: 35230175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
